Aripiprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aripiprazole: From Schizophrenia to Major Affective Disorder
One-Sentence Summary
Aripiprazole is an atypical antipsychotic originally approved for schizophrenia and bipolar mania, working through a unique dopamine/serotonin partial agonist mechanism distinct from earlier-generation antipsychotics. The TxGNN model predicts it may be effective for Major Affective Disorder (encompassing major depressive disorder and bipolar depression), with over 20 clinical trials — including multiple completed Phase 3 RCTs — and 20 publications providing strong supporting evidence for this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia; Bipolar Disorder (manic/mixed episodes) |
| Predicted New Indication | Major Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L1 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Aripiprazole is a third-generation atypical antipsychotic with a pharmacologically distinctive profile: it acts as a partial agonist at dopamine D2/D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at 5-HT2A receptors. Unlike conventional antipsychotics that simply block D2 receptors, aripiprazole's partial agonism acts as a functional stabiliser — dampening dopamine activity in hyperdopaminergic regions (striatum) while augmenting it in hypodopaminergic areas (prefrontal cortex). This dual-pathway modulation directly addresses the neurochemical imbalances observed in mood disorders.
The biological bridge between schizophrenia and major affective disorder is well established: both involve dysregulation of the prefrontal-limbic dopamine/serotonin axis. In treatment-resistant depression (TRD), inadequate dopaminergic tone in the prefrontal cortex contributes to anhedonia, executive dysfunction, and treatment non-response. Aripiprazole's 5-HT1A partial agonism additionally provides anxiolytic and antidepressant-adjacent activity, while 5-HT2A antagonism augments serotonergic antidepressant effects when co-administered with SSRIs or SNRIs.
This mechanistic rationale is borne out in regulatory practice: the US FDA has already approved aripiprazole as an adjunctive treatment for major depressive disorder inadequately responsive to antidepressants, and for bipolar I disorder maintenance. The TxGNN prediction therefore reflects a clinically validated mechanism, and the primary question for New Zealand is not biological plausibility but rather whether the evidence base justifies local registration and reimbursement.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00683852 | Phase 3 | Completed | 225 | Double-blind, placebo-controlled RCT evaluating reduced-dose aripiprazole as adjunct to antidepressant therapy (ADT) in MDD patients with inadequate prior ADT response — the most directly relevant core trial |
| NCT00876343 | Phase 3 | Completed | 586 | Placebo-controlled parallel-group study of aripiprazole adjunctive to SSRI or SNRI in MDD; assessed efficacy and safety of co-administration |
| NCT00105196 | Phase 3 | Completed | 349 | 14-week RCT of aripiprazole adjunctive to open-label ADT in MDD patients with incomplete response to 8-week prospective antidepressant trial |
| NCT02046564 | Phase 3 | Completed | 412 | Evaluated ASC-01 (fixed-dose aripiprazole/sertraline combination) vs sertraline monotherapy in MDD with incomplete sertraline response |
| NCT01567527 | Phase 3 | Completed | 731 | 52-week RCT of aripiprazole IM depot as maintenance treatment in bipolar I disorder; assessed time to recurrence of any mood episode |
| NCT00953745 | N/A | Completed | 43 | PET/fMRI mechanistic study examining dopaminergic pathway as primary mechanism for aripiprazole augmentation in treatment-resistant depression |
| NCT00873795 | N/A | Completed | 41 | Direct dose-combination study of aripiprazole 2.5 mg + sertraline 50 mg in treatment-naive major depressive patients; compared with sertraline monotherapy |
| NCT01111552 | Phase 3 | Terminated | 237 | Double-blind RCT of oral aripiprazole/escitalopram combination in MDD with incomplete escitalopram response; terminated early but partial data available |
| NCT07153406 | Phase 3 | Not Yet Recruiting | 220 | Head-to-head comparison of esketamine nasal spray vs aripiprazole (both with SSRI/SNRI) in elderly (>60 years) treatment-resistant MDD; start planned September 2025 |
| NCT03423680 | Phase 3 | Recruiting | 390 | 8-week double-blind RCT of aripiprazole adjunctive to mood stabiliser for major depressive episodes in bipolar I or II disorder |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38669232 | 2024 | Systematic Review & Meta-analysis of RCTs | PLoS ONE | First large-scale systematic review and meta-analysis of RCTs evaluating aripiprazole or bupropion augmentation/switching in TRD and MDD; provides highest-tier synthesis of aripiprazole efficacy and safety |
| 34986373 | 2022 | Systematic Review & Network Meta-analysis | Journal of Affective Disorders | Compared augmentation agents in adult TRD via NMA combining direct and indirect evidence; aripiprazole emerged as among the most efficacious augmentation agents |
| 38219278 | 2024 | Systematic Review | Neuropsychopharmacology Reports | Network meta-analysis comparing brexpiprazole, aripiprazole, and placebo for Japanese patients with MDD inadequately responsive to antidepressants; directly relevant to Asian-Pacific regulatory context |
| 35861202 | 2023 | Systematic Review & Meta-analysis | Journal of Psychopharmacology | Evaluated augmentation and combination treatments for early-stage TRD; supports aripiprazole as a first-line augmentation choice |
| 34167174 | 2021 | Systematic Review & Meta-analysis | Primary Care Companion for CNS Disorders | Assessed long-term (≥6 months) efficacy and tolerability of adjunctive aripiprazole for MDD; primary outcome was remission from depression |
| 36239033 | 2023 | RCT | Journal of Psychopharmacology | Randomised, double-blind, placebo-controlled trial of aripiprazole adjunctive therapy in MDD patients with prominent somatic symptoms; included EEG biomarker assessment |
| 37149344 | 2023 | Review | Psychiatric Clinics of North America | Comprehensive review of pharmacotherapy for TRD; identifies atypical antipsychotics — led by aripiprazole and brexpiprazole — as the most widely studied augmentation class |
| 36855876 | 2023 | Review | American Journal of Psychiatry | Examined how antipsychotics fit into the rapidly evolving TRD therapeutic landscape; contextualises aripiprazole against newer agents (esketamine, brexpiprazole) |
| 37815563 | 2023 | Review | JAMA | Comprehensive review of bipolar disorder diagnosis and treatment in JAMA; covers aripiprazole's role in the bipolar disorder spectrum |
| 21254788 | 2011 | Review | CNS Drugs | Foundational overview of aripiprazole's clinical trial data as adjunctive therapy for MDD; summarises the mechanistic rationale and large-scale Phase 3 trial programme leading to FDA approval |
New Zealand Market Information
Aripiprazole is currently not registered in New Zealand (Medsafe). No product authorizations are on file, and the drug is not available through standard market channels.
Note: Aripiprazole holds regulatory approvals in multiple major markets including the United States (FDA), European Union (EMA), Japan (PMDA), and Australia (TGA) for indications including schizophrenia, bipolar I disorder, and MDD augmentation. The absence of New Zealand registration represents a market access gap rather than an evidence gap.
Safety Considerations
Formal package insert safety data for the New Zealand market is not available in this evidence pack. Based on the broader clinical profile of aripiprazole as an atypical antipsychotic with FDA approval and decades of post-marketing surveillance, the following general considerations apply:
- Metabolic profile: Aripiprazole has a comparatively favourable metabolic profile among second-generation antipsychotics, with lower propensity for weight gain and dyslipidaemia than olanzapine or quetiapine
- Impulse control: A systematic review (PMID 38227009) identified reports of aripiprazole-associated impulsive-compulsive behaviours (gambling, hypersexuality, compulsive eating) — monitor at dose increases
- Akathisia: Reported at higher rates with aripiprazole than some comparators; particularly relevant in depression where it may be misattributed to anxiety or agitation
Please refer to the approved package insert and Medsafe product information for complete warnings, contraindications, and drug interaction data before clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence base for aripiprazole in major affective disorder — specifically as augmentation therapy for MDD inadequately responsive to antidepressants, and as maintenance treatment in bipolar I disorder — meets L1 criteria, with multiple completed Phase 3 RCTs totalling thousands of participants and FDA/EMA regulatory approval already in place. The TxGNN prediction score of 99.62% reflects a mechanistically well-grounded association. The primary barrier is not scientific but regulatory and market-access.
To proceed, the following is needed:
- Medsafe registration pathway: Determine whether to pursue a full new medicine application or abridged evaluation based on overseas approvals (FDA/EMA); an abridged pathway referencing existing regulatory packages would be the most efficient route
- Full safety dossier: Obtain the complete package insert with TFDA/FDA/EMA-approved warnings, contraindications, and drug interaction profile to complete safety assessment
- Indication scoping: Clarify whether the target indication is (a) MDD augmentation, (b) bipolar I maintenance, or (c) both — each may require a separate submission or label section
- Local pharmacovigilance plan: Given the impulse control adverse effect signal, a risk minimisation strategy (prescriber education, patient monitoring programme) should be designed before launch
- Health economic assessment: Evaluate cost-effectiveness relative to currently available augmentation agents (e.g., quetiapine, lithium) in the New Zealand healthcare context, to support PHARMAC funding consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.